JP2009513663A5 - - Google Patents

Download PDF

Info

Publication number
JP2009513663A5
JP2009513663A5 JP2008537953A JP2008537953A JP2009513663A5 JP 2009513663 A5 JP2009513663 A5 JP 2009513663A5 JP 2008537953 A JP2008537953 A JP 2008537953A JP 2008537953 A JP2008537953 A JP 2008537953A JP 2009513663 A5 JP2009513663 A5 JP 2009513663A5
Authority
JP
Japan
Prior art keywords
mice
treated
fbn1c1039g
losartan
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008537953A
Other languages
English (en)
Japanese (ja)
Other versions
JP5602365B2 (ja
JP2009513663A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/041846 external-priority patent/WO2007050793A2/en
Publication of JP2009513663A publication Critical patent/JP2009513663A/ja
Publication of JP2009513663A5 publication Critical patent/JP2009513663A5/ja
Application granted granted Critical
Publication of JP5602365B2 publication Critical patent/JP5602365B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008537953A 2005-10-25 2006-10-25 マルファン症候群及び関連疾患を治療するための方法及び組成物。 Expired - Fee Related JP5602365B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72997605P 2005-10-25 2005-10-25
US60/729,976 2005-10-25
PCT/US2006/041846 WO2007050793A2 (en) 2005-10-25 2006-10-25 Methods and compositions for the treatment of marfan syndrome and associated disorders

Publications (3)

Publication Number Publication Date
JP2009513663A JP2009513663A (ja) 2009-04-02
JP2009513663A5 true JP2009513663A5 (enExample) 2012-10-04
JP5602365B2 JP5602365B2 (ja) 2014-10-08

Family

ID=37968564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008537953A Expired - Fee Related JP5602365B2 (ja) 2005-10-25 2006-10-25 マルファン症候群及び関連疾患を治療するための方法及び組成物。

Country Status (5)

Country Link
US (1) US8597646B2 (enExample)
EP (2) EP2862867A3 (enExample)
JP (1) JP5602365B2 (enExample)
ES (1) ES2526705T3 (enExample)
WO (1) WO2007050793A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586822B2 (en) * 2007-11-02 2013-11-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for producing a non human model for aortic aneurysm
US9567637B2 (en) 2009-04-20 2017-02-14 The University Of Tokyo Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease
CN102639134A (zh) * 2009-10-01 2012-08-15 和谐进化股份有限公司 使用基质金属蛋白酶-2抑制剂治疗动脉瘤样扩张、血管壁薄弱、特别是腹主动脉瘤和胸主动脉瘤的方法
RU2456925C1 (ru) * 2011-03-15 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития идиопатического сколиоза у детей
WO2012142476A2 (en) * 2011-04-14 2012-10-18 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2013078261A1 (en) 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
JP6240379B2 (ja) * 2012-10-06 2017-11-29 株式会社 バイオエルティ 循環型TGF−βの抑制剤
US20150284455A1 (en) * 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
BR112015021595A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
JP2016520592A (ja) * 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
CU20180088A7 (es) 2016-02-17 2019-05-03 Novartis Ag Anticuerpos anti tgfbeta 2
WO2018160987A1 (en) * 2017-03-02 2018-09-07 The Johns Hopkins University Map kinase pathway targets for the treatment of marfan syndrome
WO2019046791A1 (en) 2017-09-01 2019-03-07 The Johns Hopkins University TARGETED EPIGENETIC THERAPY FOR AERIAL CONDITION OF AERTICAL HERITATION
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CN116867797A (zh) * 2020-12-23 2023-10-10 韩国科学技术研究院 能够抑制TGF-β信号传导的新型肽及其应用
WO2024052343A1 (en) * 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
WO2025085731A1 (en) * 2023-10-18 2025-04-24 Children's National Medical Center TRANSFORMING GROWTH FACTOR ß (TGF-ß) OLIGONUCLEOTIDE COMBINATION THERAPY FOR TREATING MUSCULOSKELETAL DISEASES

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
WO1990000194A1 (en) 1988-06-28 1990-01-11 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
DK0494264T3 (da) 1989-09-29 1998-01-26 Jolla Cancer Res Found Inhibering af transformede vækstfaktor til hindring af akkumulation af ekstracellulær matrix
DK0502036T3 (da) 1989-11-22 1996-05-06 Genentech Inc Latens-associeret peptid og anvendelser herfor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ TGF−β型受容体cDNAおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
WO1993009800A1 (en) 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
EP0616536B1 (en) 1991-12-04 1999-03-17 La Jolla Cancer Research Foundation Use of decorin or biglycan for the manufacture of a medicament in the treatment of diabetes-associated pathology
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
AU3920693A (en) 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
WO1993019783A1 (en) 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994009812A1 (en) 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
WO1994009815A1 (en) 1992-10-29 1994-05-11 Celtrix Pharmaceuticals, Inc. USES OF TGF-β RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT
CA2147754A1 (en) 1992-10-30 1994-05-11 Michelle Letarte Compositions and methods for modifying the regulatory activity of tgf- .beta.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
WO1995010610A1 (en) 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
JPH09512910A (ja) 1994-05-04 1997-12-22 マウント・サイナイ・ホスピタル・コーポレイション TGF−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤
US5968770A (en) 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5550127A (en) * 1995-09-07 1996-08-27 Pantano; James A. Method of treatment for eiph in racing stock
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5912224A (en) 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
JP2000510112A (ja) 1996-04-30 2000-08-08 ジェンザイム コーポレーション TGF―β拮抗物質としてのプロラクチンの使用方法
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
WO1998003663A1 (en) 1996-07-24 1998-01-29 Chugai Seiyaku Kabushiki Kaisya Human taki dna encoding the same
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
WO1998007735A1 (en) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6017755A (en) 1996-08-22 2000-01-25 Hsc Research & Development Limited MADR2 tumour suppressor gene
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
JPH10114676A (ja) * 1996-10-09 1998-05-06 Toray Ind Inc β型トランスフォーミング増殖因子産生抑制剤
ATE312620T1 (de) 1996-10-25 2005-12-15 Ethicon Inc Testverfahren für antifibrotischen wirkstoff
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
PT975771E (pt) 1997-04-18 2007-10-01 Biogen Idec Inc Proteínas de fusão da região constante da imunoglobulina/receptor do ftc-beta do tipoii
JPH10295381A (ja) 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
WO1998053068A1 (en) 1997-05-20 1998-11-26 Ludwig Institute For Cancer Research Smad7 and uses thereof
AU7705398A (en) 1997-05-28 1998-12-30 President And Fellows Of Harvard College Methods and reagents for modulating tgf-beta superfamily signaling
AU8623798A (en) 1997-06-02 1998-12-21 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Smad-interacting polypeptides and their use
JP3626206B2 (ja) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Smad6及びその使用
CA2324476A1 (en) 1998-03-27 1999-10-07 Eli Lilly And Company Treatment and prevention of vascular disease
EP1140041A2 (en) * 1999-01-05 2001-10-10 University of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
JP2003509030A (ja) * 1999-09-17 2003-03-11 アイシス・ファーマシューティカルス・インコーポレーテッド トランスフォーミング成長因子−β発現のアンチセンスオリゴヌクレオチド調節
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
JP2005519881A (ja) * 2001-12-11 2005-07-07 ファイブローゲン、インコーポレーテッド 眼プロセスの抑制方法
EP1575506A4 (en) * 2002-07-25 2008-04-23 Scios Inc METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
AU2004267425B2 (en) * 2003-08-13 2010-10-21 The Board Of Trustees Of The University Of Illinois Silencing of TGF-beta receptor type II expression by sIRNA
US7462185B1 (en) * 2004-12-23 2008-12-09 Cardican Inc. Intravascular stapling tool
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Similar Documents

Publication Publication Date Title
JP2009513663A5 (enExample)
Ogawa et al. The role of leukotrienes in airway inflammation
Brown et al. The microbiota protects from viral-induced neurologic damage through microglia-intrinsic TLR signaling
Lee et al. Resolvin E1 reverses experimental periodontitis and dysbiosis
Ghasemi et al. The role of NMDA receptors in the pathophysiology and treatment of mood disorders
Stone et al. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
D’Alessandro et al. Eosinophilic esophagitis: from pathophysiology to treatment
Pietropaoli et al. Occurrence of spontaneous periodontal disease in the SAMP1/YitFc murine model of Crohn disease
Woo et al. NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care
Chang et al. Odontogenic infection involving the secondary fascial space in diabetic and non-diabetic patients: a clinical comparative study
Haussmann et al. Minireview: Lithium: A therapeutic option in Alzheimer’s disease and its prodromal stages?
FI2839836T4 (fi) Probiootit käytettäväksi vähennettäessä hengityselintaudin oireita
JP2023113650A5 (enExample)
JP2009513660A5 (enExample)
Anderson et al. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson’s disease
Domm et al. Affect of early life oxygen exposure on proper lung development and response to respiratory viral infections
JP2012502909A5 (enExample)
Cacabelos et al. APOE-TOMM40 in the Pharmacogenomics of Dementia
Liu et al. Are dexmedetomidine and olanzapine suitable to control delirium in critically ill elderly patients? A retrospective cohort study
JP2012527438A5 (enExample)
Amano et al. Opposite associations between the rs3845446 single-nucleotide polymorphism of the CACNA1E gene and postoperative pain-related phenotypes in gastrointestinal surgery versus previously reported orthognathic surgery
Holloman et al. Indole-3-carbinol attenuates lipopolysaccharide-induced acute respiratory distress syndrome through activation of AhR: role of CCR2+ monocyte activation and recruitment in the regulation of CXCR2+ neutrophils in the lungs
Xu et al. Traversing the epigenetic landscape: DNA methylation from retina to brain in development and disease
Xu et al. Natural adrenocorticotropic hormone (ACTH) relieves acute inflammation in gout patients by changing the function of macrophages
CN109069471A (zh) 用于治疗流感病毒的组合物和方法